Want to join the conversation?
$ASGN said its BoD approved a new stock repurchase program, under which it may repurchase up to $150MM of its common stock over the next 2 years. This program is effective immediately and supersedes the previous $100MM repurchase authorization ($98MM was remaining under the authorization).
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.